The Educational Program of Macrophages toward a Hyperprogressive Disease-Related Phenotype Is Orchestrated by Tumor-Derived Extracellular Vesicles
暂无分享,去创建一个
G. Sozzi | L. De Cecco | C. Moscheni | E. Tagliabue | T. Triulzi | M. Sommariva | L. Sfondrini | N. Gagliano | F. Arnaboldi | Valentino Le Noci | M. Moro | P. Sartori | Cristina Borzi | S. Indino | Giancarla Bernardo | G. Bernardo
[1] T. Haykal,et al. Tumor-intrinsic NLRP3-HSP70-TLR4 axis drives premetastatic niche development and hyperprogression during anti–PD-1 immunotherapy , 2022, Science Translational Medicine.
[2] J. Minna,et al. Tumor cells modulate macrophage phenotype in a novel in vitro co-culture model of the non-small cell lung cancer tumor microenvironment. , 2022, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[3] N. Sun,et al. Systematic analysis of IL-6 as a predictive biomarker and desensitizer of immunotherapy responses in patients with non-small cell lung cancer , 2022, BMC Medicine.
[4] Bosen You,et al. Tumor-associated macrophage-derived exosomes transmitting miR-193a-5p promote the progression of renal cell carcinoma via TIMP2-dependent vasculogenic mimicry , 2022, Cell Death & Disease.
[5] Yangchun Chen,et al. miR-146a promotes M2 macrophage polarization and accelerates diabetic wound healing by inhibiting the TLR4/NF-κB axis. , 2022, Journal of molecular endocrinology.
[6] Y. Chan,et al. Cytokine Release Syndrome in Cancer Patients Receiving Immune Checkpoint Inhibitors: A Case Series of 25 Patients and Review of the Literature , 2022, Frontiers in Immunology.
[7] Jun Zhang,et al. Targeting interleukin-1β and inflammation in lung cancer , 2022, Biomarker research.
[8] J. Weiss,et al. Tumor-Infiltrating Myeloid Cells Co-Express TREM1 and TREM2 and Elevated TREM-1 Associates With Disease Progression in Renal Cell Carcinoma , 2022, Frontiers in Oncology.
[9] C. D’Souza-Schorey,et al. Tumor-Derived Extracellular Vesicles: A Means of Co-opting Macrophage Polarization in the Tumor Microenvironment , 2021, Frontiers in Cell and Developmental Biology.
[10] P. Allavena,et al. Macrophages and cancer stem cells: a malevolent alliance , 2021, Molecular Medicine.
[11] E. Tagliabue,et al. Toll Like Receptors as Sensors of the Tumor Microbial Dysbiosis: Implications in Cancer Progression , 2021, Frontiers in Cell and Developmental Biology.
[12] M. D. Peris-Díaz,et al. Current Landscape of Non-Small Cell Lung Cancer: Epidemiology, Histological Classification, Targeted Therapies, and Immunotherapy , 2021, Cancers.
[13] M. Colombo,et al. Macrophages Impair TLR9 Agonist Antitumor Activity through Interacting with the Anti-PD-1 Antibody Fc Domain , 2021, Cancers.
[14] J. Iovanna,et al. NUPR1: A Critical Regulator of the Antioxidant System , 2021, Cancers.
[15] D. Chan,et al. The Impact of the Tumor Microenvironment on Macrophage Polarization in Cancer Metastatic Progression , 2021, International journal of molecular sciences.
[16] W. Jiang,et al. NUPR1 and its potential role in cancer and pathological conditions (Review). , 2021, International journal of oncology.
[17] G. Kroemer,et al. NUPR1 is a critical repressor of ferroptosis , 2021, Nature Communications.
[18] S. Ramaswamy,et al. Preclinical characterization of dostarlimab, a therapeutic anti-PD-1 antibody with potent activity to enhance immune function in in vitro cellular assays and in vivo animal models , 2021, mAbs.
[19] Lianmei Zhao,et al. Exosome-mediated communication between tumor cells and tumor-associated macrophages: implications for tumor microenvironment , 2021, Oncoimmunology.
[20] D. Lambrechts,et al. IL1β Promotes Immune Suppression in the Tumor Microenvironment Independent of the Inflammasome and Gasdermin D , 2020, Cancer Immunology Research.
[21] T. Hirano. IL-6 in inflammation, autoimmunity and cancer , 2020, International immunology.
[22] Ting Zhang,et al. Tumor-Associated Macrophages in Tumor Immunity , 2020, Frontiers in Immunology.
[23] C. Moscheni,et al. Mechanisms of hyperprogressive disease after immune checkpoint inhibitor therapy: what we (don’t) know , 2020, Journal of experimental & clinical cancer research : CR.
[24] A. Leelahavanichkul,et al. Over-expression of miR-223 induces M2 macrophage through glycolysis alteration and attenuates LPS-induced sepsis mouse model, the cell-based therapy in sepsis , 2020, PloS one.
[25] M. Bosco,et al. Targeting Mononuclear Phagocyte Receptors in Cancer Immunotherapy: New Perspectives of the Triggering Receptor Expressed on Myeloid Cells (TREM-1) , 2020, Cancers.
[26] D. Matei,et al. MicroRNA-155 Implication in M1 Polarization and the Impact in Inflammatory Diseases , 2020, Frontiers in Immunology.
[27] Xikun Zhou,et al. Tumor-Associated Macrophages: Recent Insights and Therapies , 2020, Frontiers in Oncology.
[28] S. Dubinett,et al. The Role of Interleukin 1β in the Pathogenesis of Lung Cancer , 2020, JTO clinical and research reports.
[29] Raghu Kalluri,et al. The biology, function, and biomedical applications of exosomes , 2020, Science.
[30] A. Morgan,et al. Standardized protocols for differentiation of THP-1 cells to macrophages with distinct M(IFNγ+LPS), M(IL-4) and M(IL-10) phenotypes. , 2020, Journal of immunological methods.
[31] M. Koch,et al. Hot EVs - how temperature affects extracellular vesicles. , 2019, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.
[32] Xiaoying Dong,et al. Beyond T Cells: Understanding the Role of PD-1/PD-L1 in Tumor-Associated Macrophages , 2019, Journal of immunology research.
[33] S. Castiglioni,et al. 3D Quantitative and Ultrastructural Analysis of Mitochondria in a Model of Doxorubicin Sensitive and Resistant Human Colon Carcinoma Cells , 2019, Cancers.
[34] N. Meyer,et al. The TNF Paradox in Cancer Progression and Immunotherapy , 2019, Front. Immunol..
[35] Feng-ming Ding,et al. CXCR4 knockdown prevents inflammatory cytokine expression in macrophages by suppressing activation of MAPK and NF-κB signaling pathways , 2019, Cell & Bioscience.
[36] F. Greten,et al. Inflammation and Cancer: Triggers, Mechanisms, and Consequences. , 2019, Immunity.
[37] Yuan He,et al. The NLRP3 Inflammasome: An Overview of Mechanisms of Activation and Regulation , 2019, International journal of molecular sciences.
[38] Haiyang Xie,et al. Blocking Triggering Receptor Expressed on Myeloid Cells‐1‐Positive Tumor‐Associated Macrophages Induced by Hypoxia Reverses Immunosuppression and Anti‐Programmed Cell Death Ligand 1 Resistance in Liver Cancer , 2019, Hepatology.
[39] M. Broggini,et al. LKB1 deficiency renders non-small-cell lung cancer cells sensitive to ERK inhibitors.: ERK inhibitors in LKB1 mutated NSCLC. , 2019, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[40] Jiao Guo,et al. M2b macrophage polarization and its roles in diseases , 2018, Journal of leukocyte biology.
[41] K. Khazim,et al. The Role of Interleukin-1 in the Pathogenesis of Cancer and its Potential as a Therapeutic Target in Clinical Practice , 2018, Oncology and Therapy.
[42] D. Djureinovic,et al. Expression of scavenger receptor MARCO defines a targetable tumor‐associated macrophage subset in non‐small cell lung cancer , 2018, International journal of cancer.
[43] V. Torri,et al. Antibody–Fc/FcR Interaction on Macrophages as a Mechanism for Hyperprogressive Disease in Non–small Cell Lung Cancer Subsequent to PD-1/PD-L1 Blockade , 2018, Clinical Cancer Research.
[44] J. Tosello,et al. Tumor Necrosis Factor α and Regulatory T Cells in Oncoimmunology , 2018, Front. Immunol..
[45] M. Dessing,et al. TREM‐1 and its potential ligands in non‐infectious diseases: from biology to clinical perspectives , 2017, Pharmacology & therapeutics.
[46] A. Longatto-Filho,et al. High systemic IL-6 is associated with worse prognosis in patients with non-small cell lung cancer , 2017, PloS one.
[47] Daniel M. Corey,et al. PD-1 expression by tumor-associated macrophages inhibits phagocytosis and tumor immunity , 2017, Nature.
[48] S. Snapper,et al. Anti-inflammatory effect of IL-10 mediated by metabolic reprogramming of macrophages , 2017, Science.
[49] Lin-lin Sun,et al. 2-Deoxyglucose Suppresses ERK Phosphorylation in LKB1 and Ras Wild-Type Non-Small Cell Lung Cancer Cells , 2016, PloS one.
[50] Charles Ferté,et al. Hyperprogressive Disease Is a New Pattern of Progression in Cancer Patients Treated by Anti-PD-1/PD-L1 , 2016, Clinical Cancer Research.
[51] Yutian Li,et al. MiRNA-Mediated Macrophage Polarization and its Potential Role in the Regulation of Inflammatory Response , 2016, Shock.
[52] B. Brüne,et al. Lipocalin 2 from macrophages stimulated by tumor cell–derived sphingosine 1-phosphate promotes lymphangiogenesis and tumor metastasis , 2016, Science Signaling.
[53] S. Hanash,et al. IL6 Blockade Reprograms the Lung Tumor Microenvironment to Limit the Development and Progression of K-ras-Mutant Lung Cancer. , 2016, Cancer research.
[54] S. Safe,et al. MicroRNA-223 is a crucial mediator of PPARγ-regulated alternative macrophage activation. , 2015, The Journal of clinical investigation.
[55] Xiaojun Liu,et al. Blockade of Programmed Death 1 Augments the Ability of Human T Cells Engineered to Target NY-ESO-1 to Control Tumor Growth after Adoptive Transfer , 2015, Clinical Cancer Research.
[56] S. Tsai,et al. EGFR over-expression in non-small cell lung cancers harboring EGFR mutations is associated with marked down-regulation of CD82. , 2015, Biochimica et biophysica acta.
[57] M. Kortylewski,et al. Macrophage immunomodulation by breast cancer-derived exosomes requires Toll-like receptor 2-mediated activation of NF-κB , 2014, Scientific Reports.
[58] L. Boon,et al. Lipocalin 2 deactivates macrophages and worsens pneumococcal pneumonia outcomes. , 2013, The Journal of clinical investigation.
[59] James A. Hutchinson,et al. IFN-γ-induced iNOS expression in mouse regulatory macrophages prolongs allograft survival in fully immunocompetent recipients. , 2013, Molecular therapy : the journal of the American Society of Gene Therapy.
[60] A. Balmain,et al. Guidelines for the welfare and use of animals in cancer research , 2010, British Journal of Cancer.
[61] M. Meyerson,et al. Mutations in the LKB1 tumour suppressor are frequently detected in tumours from Caucasian but not Asian lung cancer patients , 2008, British Journal of Cancer.
[62] Jill P. Mesirov,et al. GSEA-P: a desktop application for Gene Set Enrichment Analysis , 2007, Bioinform..
[63] J. Mesirov,et al. GenePattern 2.0 , 2006, Nature Genetics.
[64] Marian F Young,et al. The matrix component biglycan is proinflammatory and signals through Toll-like receptors 4 and 2 in macrophages. , 2005, The Journal of clinical investigation.
[65] J. Mauël,et al. CD69 and regulation of the immune function. , 1999, Immunopharmacology and immunotoxicology.
[66] T. Oegema,et al. A fragment of α-actinin promotes monocyte/macrophage maturation in vitro , 1999 .